Mendus AB (publ)
The answer first
Does Mendus beat the market?
No, Mendus has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 50% of Nordic stocks
- Quality83
- Value60
- Trend13
No. 59 of 195 in healthcare
Max for seven days
Follow Mendus with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Mendus
Your first answer is free, no account needed.
Do you own Mendus, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Mendus and a few more. Free, no card.
Super Stock+44.6%In short
- Mendus has fallen 35.0% over the past year, including dividends.
- Overall, Mendus ranks better than 50% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 94.5%. The price is 99.5% below its peak now.
What do analysts think of Mendus?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 50% of Nordic stocks.
No. 59 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 44 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.07
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−20.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 27 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.4
- P/SPrice divided by sales232.0
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 149 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−47.4%
- 6 months−35.7%
- 9 months−24.8%
- 12 months−35.0%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Mendus
2 funds we follow own Mendus. The share is how much of the fund the stock makes up.
- Sweden2
From the funds' latest known holdings.
About Mendus
Mendus AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 27 employees.
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022.


See the full analysis of Mendus.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card